Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Brief description of study
This is a prospective, randomized, placebo-controlled, multicenter study of patients with newly diagnosed glioblastoma (nGBM) to evaluate a peptide vaccine (SurVaxM) in emulsion with Montanide given together with locally administered sargramostim plus adjuvant oral temozolomide (TMZ) (Arm A) versus saline-Montanide emulsion with locally administered saline (instead of sargramostim) plus adjuvant oral temozolomide (TMZ) (Arm B).
Clinical Study Identifier: s22-00457
ClinicalTrials.gov Identifier: NCT05163080
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
